Compare HRMY & BLBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | BLBD |
|---|---|---|
| Founded | 2017 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Construction/Ag Equipment/Trucks |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2020 | 2013 |
| Metric | HRMY | BLBD |
|---|---|---|
| Price | $27.73 | $55.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $46.70 | ★ $67.20 |
| AVG Volume (30 Days) | ★ 900.4K | 334.2K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.97 | ★ 22.78 |
| EPS | ★ 2.71 | 0.94 |
| Revenue | $868,453,000.00 | ★ $1,480,099,000.00 |
| Revenue This Year | $19.87 | $6.14 |
| Revenue Next Year | $12.49 | $6.56 |
| P/E Ratio | ★ $10.22 | $56.89 |
| Revenue Growth | ★ 21.51 | 9.87 |
| 52 Week Low | $25.52 | $30.15 |
| 52 Week High | $40.87 | $62.90 |
| Indicator | HRMY | BLBD |
|---|---|---|
| Relative Strength Index (RSI) | 32.88 | 50.57 |
| Support Level | $25.71 | $53.24 |
| Resistance Level | $28.99 | $56.42 |
| Average True Range (ATR) | 0.75 | 1.78 |
| MACD | 0.22 | -0.23 |
| Stochastic Oscillator | 26.60 | 45.59 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.